In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00118153" target="_blank" >RIV/00216224:14110/20:00118153 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/20:00072694
Result on the web
<a href="https://www.nature.com/articles/s41375-019-0591-9" target="_blank" >https://www.nature.com/articles/s41375-019-0591-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-019-0591-9" target="_blank" >10.1038/s41375-019-0591-9</a>

Result language
angličtina
Original language name
In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent
Original language description
Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description